In today’s briefing:
- HDFC Bank – Ranks 2nd After Merger Compared With Asia Pacific Banks
- Japan Weekly | Oasis Prescribe New Medicine for Tsuruha
- China Healthcare Weekly (Jun.30)-Surgical Robots, Medical Equipment New Policy, Pfizer’s Frustration
HDFC Bank – Ranks 2nd After Merger Compared With Asia Pacific Banks
- New HDFC Bank appears to have far better returns and credit metrics that large Asian peers
- Pro-Forma amalgamation puts HDFC Bank as 2nd largest bank in Asia Pacific in market cap
- Comparably large banks in Asia are concentrated in China, where credit metrics are opaque
Japan Weekly | Oasis Prescribe New Medicine for Tsuruha
- Oasis has launched a hostile campaign against Tsuruha, one of the largest drug store chains in Japan
- The company’s corporate governance needs a serious overhaul – the board is entrenched and dominated by the founding families
- Shareholders will need to elect a Board with more independence and a greater skillset to navigate industry consolidation
China Healthcare Weekly (Jun.30)-Surgical Robots, Medical Equipment New Policy, Pfizer’s Frustration
- The National Health Commission released “14th Five-Year Plan for the Configuration of Large Medical Equipment”, which should drive the upgrading of the whole industry chain and accelerate the import substitution.
- The gap between Chinese and Western hospitals can lead to many differences in the logic of future commercialization, such as surgical robots and other high-priced innovative medical devices in China.
- The efficacy/safety standards of GLP-1 drugs have been raised sufficiently high. If latecomers’ products fail to be better than Semaglutide/Tirzepatide/Orforglipron, it’s difficult to gain market share through “fast-follow strategy”.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
